Cullinan Therapeutics Inc
Company Profile
Business description
Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Its development pipeline comprises the following drug candidates: CLN-978, a CD19xCD3 bispecific T cell engager that is being developed for autoimmune diseases; CLN-049, a FLT3xCD3 bispecific T cell engager being evaluated in an ongoing clinical trial in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); Velinotamig, a BCMAxCD3 bispecific T cell engager being developed to counter autoimmune diseases; and Zipalertinib, being developed as a treatment for non-small cell lung cancer. Additionally, the company is developing several preclinical programs in autoimmune diseases and oncology.
Contact
One Main Street
Suite 1350
CambridgeMA02142
USAT: +1 617 410-4650
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
109
Stocks News & Analysis
stocks
What did Morningstar subscribers buy and sell during June?
stocks
Australia’s largest gold miner downgraded on a falling gold price
stocks
Cheap ASX share pays a heavy price for NRL rights
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,958.90 | 38.70 | -0.43% |
| CAC 40 | 8,364.65 | 25.69 | 0.31% |
| DAX 40 | 25,114.25 | 47.16 | 0.19% |
| Dow JONES (US) | 52,498.64 | 138.37 | -0.26% |
| FTSE 100 | 10,498.29 | 1.00 | 0.01% |
| HKSE | 24,213.72 | 38.60 | 0.16% |
| NASDAQ | 25,873.18 | 408.43 | -1.55% |
| Nikkei 225 | 66,801.13 | 441.59 | -0.66% |
| NZX 50 Index | 13,658.03 | 65.17 | -0.47% |
| S&P 500 | 7,515.34 | 60.05 | -0.79% |
| S&P/ASX 200 | 8,765.60 | 38.10 | -0.43% |
| SSE Composite Index | 3,913.79 | 82.37 | -2.06% |